Botulinum Toxin Market Analysis By Type (Botulinum Toxin Type A, Botulinum Toxin Type B), By End Use (Therapeutic, Aesthetic), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2013 - 2025
出 版 商：Grand View Research
出版日期：2017/01/10
頁 數：90頁
文件格式：PDF
價 格：
USD 4,950 (Single-User License)
USD 7,950 (Multi-User License)
USD 9,950 (Global-User License)
USD 7,950 (Multi-User License)
USD 9,950 (Global-User License)
The global botulinum toxin (BNT) market is expected to reach a value of USD 7.3 billion by 2025. The constant introduction of innovative products for enhancement of aesthetic appeal supporting minimally invasive aesthetic treatments is the prime factor driving the growth of the market.
In addition, rapid growth of the sector is attributed to the rising demand for minimally invasive or non-invasive procedures. These procedures provide advantages such as small incision, shorter hospital stay and rapid wound healing, and hence lead to larger acceptance and demand. In addition, availability of wide variety of minimally invasive or non-invasive treatment options is pushing the global botulinum toxin market towards growth.
Also, the successful completion of research projects is expected to expand the applications of presently approved products. Companies are trying to widen the application of botulinum toxin in therapeutic area through various research activities. For instance, Botox by Allergan received the U.S. FDA approval for the treatment of strabismus (crossed eyes) and blepharospasm associated with dystonia in 1989. Furthermore, in 2004, Botox was approved by the U.S. FDA for hyperidrosis, cervical dystonia, upper limb spasticity, chronic migraine and urinary incontinence in 2009, 2010 and 2011 respectively. Hence, these factors all together will aid in boosting the growth of BNT sales during the forecast period.
Further Key Findings from the Study Suggest:
The rapid adoption of minimally invasive treatment is augmenting the growth of neurotoxins market.
The botulinum toxin type A segment accounted for the largest share in 2015 and is also anticipated to be the fastest growing segment during the forecast period
In 2015, North America dominated the global space with the largest revenue share owing to high demand for minimally invasive or non-invasive aesthetic treatments
Asia Pacific is expected to emerge as the fastest growing region during the forecast period, mainly due to growing social awareness regarding anti-wrinkle procedures in India, China, and Japan
Major players competing in this market include but are not limited to Allergan, Inc.; Ipsen Group; Merz GmbH and Co. KGaA, Medytox,Inc.; US Worldmed, LLC; Lanzhou Institute of Biological Products. Co.Ltd. and Revance Therapeutics, Inc.
In addition, rapid growth of the sector is attributed to the rising demand for minimally invasive or non-invasive procedures. These procedures provide advantages such as small incision, shorter hospital stay and rapid wound healing, and hence lead to larger acceptance and demand. In addition, availability of wide variety of minimally invasive or non-invasive treatment options is pushing the global botulinum toxin market towards growth.
Also, the successful completion of research projects is expected to expand the applications of presently approved products. Companies are trying to widen the application of botulinum toxin in therapeutic area through various research activities. For instance, Botox by Allergan received the U.S. FDA approval for the treatment of strabismus (crossed eyes) and blepharospasm associated with dystonia in 1989. Furthermore, in 2004, Botox was approved by the U.S. FDA for hyperidrosis, cervical dystonia, upper limb spasticity, chronic migraine and urinary incontinence in 2009, 2010 and 2011 respectively. Hence, these factors all together will aid in boosting the growth of BNT sales during the forecast period.
Further Key Findings from the Study Suggest:
The rapid adoption of minimally invasive treatment is augmenting the growth of neurotoxins market.
The botulinum toxin type A segment accounted for the largest share in 2015 and is also anticipated to be the fastest growing segment during the forecast period
In 2015, North America dominated the global space with the largest revenue share owing to high demand for minimally invasive or non-invasive aesthetic treatments
Asia Pacific is expected to emerge as the fastest growing region during the forecast period, mainly due to growing social awareness regarding anti-wrinkle procedures in India, China, and Japan
Major players competing in this market include but are not limited to Allergan, Inc.; Ipsen Group; Merz GmbH and Co. KGaA, Medytox,Inc.; US Worldmed, LLC; Lanzhou Institute of Biological Products. Co.Ltd. and Revance Therapeutics, Inc.
Table of Contents
Chapter 1 Research Methodology
1.1 Information procurement
1.2 Data Analysis
1.3 Approaches for market estimation
1.3.1 Approach 1: Demand analysis & bottom up approach
1.3.2 Approach 2: Top down market estimation
1.3.3 Approach 3: Commodity flow and bottom up market estimation
1.3.4 Approach 4: KoL perspective based market sizing
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Botulinum Toxin Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.2 Market Driver Analysis
3.2.1 Growing population aging between 25 to 65 years of age
3.2.2 Rising demand for minimally invasive treatment
3.2.3 Expanding therapeutic use of botulinum toxin
3.3 Market Restraints Analysis
3.3.1 Risk of side effects
3.3.2 Limited reimbursement coverage
3.3.3 Misuse as bioterrorism
3.4 Penetration & growth prospect mapping
3.5 Botulinum Toxin - SWOT Analysis, By Factor (political & legal, economic and technological)
3.6 Industry Analysis - Porter’s
Chapter 4 Botulinum Toxin Market: Product Type Estimates & Trend Analysis
4.1 Botulinum Toxin Market: Product Type movement analysis
4.2 Botulinum Toxin Type A
4.2.1 Market estimates and forecast, 2013 - 2025 (USD Million)
4.3 Botox
4.3.1 Market estimates and forecast, 2013 - 2025 (USD Million)
4.4 Dysport
4.4.1 Market estimates and forecast, 2013 - 2025 (USD Million)
4.5 Xeomin
4.5.1 Market estimates and forecast, 2013 - 2025 (USD Million)
4.6 Others
4.6.1 Market estimates and forecast, 2013 - 2025 (USD Million)
4.7 Botulinum Toxin Type B
4.7.1 Market estimates and forecast, 2013 - 2025 (USD Million)
Chapter 5 Botulinum Toxin Market: End Use Estimates & Trend Analysis
5.1 Botulinum Toxin Market: End use movement analysis
5.2 Therapeutic Use
5.2.1 Market estimates and forecast, 2013 - 2025 (USD Million)
5.3 Aesthetic Use
5.3.1 Market estimates and forecast, 2013 - 2025 (USD Million)
Chapter 6 Botulinum Toxin Market: Regional Estimates &Trend Analysis, by Product Type & End Use
6.1 North America
6.1.1 U.S.
6.1.1.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.1.1.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.1.2 Canada
6.1.2.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.1.2.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.2 Europe
6.2.1 U.K.
6.2.1.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.2.1.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.2.2 Germany
6.2.2.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.2.2.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.3 Asia Pacific
6.3.1 Japan
6.3.1.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.3.1.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.3.2 China
6.3.2.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.3.2.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.4 Latin America
6.4.1 Brazil
6.4.1.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.4.1.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.4.2 Mexico
6.4.2.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.4.2.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.5 Middle East and Africa (MEA)
6.5.1 South Africa
6.5.1.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.5.1.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
Chapter 7 Competitive Landscape
7.1 Ipsen group
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Allergan Inc.
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Medytox Inc.
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 Merz GmbH and Co. KGaA
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Product Benchmarking
7.4.4 Strategic Initiatives
7.5 US Worldmed, LLC
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Product Benchmarking
7.5.4 Strategic Initiatives
7.6 Lanzhou Institute of Biological Products Co. Ltd.
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Product Benchmarking
7.6.4 Strategic Initiatives
7.7 Revance Therapeutics, Inc.
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Product Benchmarking
7.7.4 Strategic Initiatives
Chapter 1 Research Methodology
1.1 Information procurement
1.2 Data Analysis
1.3 Approaches for market estimation
1.3.1 Approach 1: Demand analysis & bottom up approach
1.3.2 Approach 2: Top down market estimation
1.3.3 Approach 3: Commodity flow and bottom up market estimation
1.3.4 Approach 4: KoL perspective based market sizing
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Botulinum Toxin Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.2 Market Driver Analysis
3.2.1 Growing population aging between 25 to 65 years of age
3.2.2 Rising demand for minimally invasive treatment
3.2.3 Expanding therapeutic use of botulinum toxin
3.3 Market Restraints Analysis
3.3.1 Risk of side effects
3.3.2 Limited reimbursement coverage
3.3.3 Misuse as bioterrorism
3.4 Penetration & growth prospect mapping
3.5 Botulinum Toxin - SWOT Analysis, By Factor (political & legal, economic and technological)
3.6 Industry Analysis - Porter’s
Chapter 4 Botulinum Toxin Market: Product Type Estimates & Trend Analysis
4.1 Botulinum Toxin Market: Product Type movement analysis
4.2 Botulinum Toxin Type A
4.2.1 Market estimates and forecast, 2013 - 2025 (USD Million)
4.3 Botox
4.3.1 Market estimates and forecast, 2013 - 2025 (USD Million)
4.4 Dysport
4.4.1 Market estimates and forecast, 2013 - 2025 (USD Million)
4.5 Xeomin
4.5.1 Market estimates and forecast, 2013 - 2025 (USD Million)
4.6 Others
4.6.1 Market estimates and forecast, 2013 - 2025 (USD Million)
4.7 Botulinum Toxin Type B
4.7.1 Market estimates and forecast, 2013 - 2025 (USD Million)
Chapter 5 Botulinum Toxin Market: End Use Estimates & Trend Analysis
5.1 Botulinum Toxin Market: End use movement analysis
5.2 Therapeutic Use
5.2.1 Market estimates and forecast, 2013 - 2025 (USD Million)
5.3 Aesthetic Use
5.3.1 Market estimates and forecast, 2013 - 2025 (USD Million)
Chapter 6 Botulinum Toxin Market: Regional Estimates &Trend Analysis, by Product Type & End Use
6.1 North America
6.1.1 U.S.
6.1.1.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.1.1.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.1.2 Canada
6.1.2.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.1.2.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.2 Europe
6.2.1 U.K.
6.2.1.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.2.1.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.2.2 Germany
6.2.2.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.2.2.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.3 Asia Pacific
6.3.1 Japan
6.3.1.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.3.1.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.3.2 China
6.3.2.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.3.2.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.4 Latin America
6.4.1 Brazil
6.4.1.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.4.1.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.4.2 Mexico
6.4.2.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.4.2.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
6.5 Middle East and Africa (MEA)
6.5.1 South Africa
6.5.1.1 Market estimates and forecast, by product type 2013 - 2025 (USD Million)
6.5.1.2 Market estimates and forecast, by end use, 2013 - 2025 (USD Million)
Chapter 7 Competitive Landscape
7.1 Ipsen group
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Allergan Inc.
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Medytox Inc.
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 Merz GmbH and Co. KGaA
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Product Benchmarking
7.4.4 Strategic Initiatives
7.5 US Worldmed, LLC
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Product Benchmarking
7.5.4 Strategic Initiatives
7.6 Lanzhou Institute of Biological Products Co. Ltd.
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Product Benchmarking
7.6.4 Strategic Initiatives
7.7 Revance Therapeutics, Inc.
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Product Benchmarking
7.7.4 Strategic Initiatives
